Bolt Biotherapeutics Stock

boltbio.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $64.6MM

Bolt Biotherapeutics is a biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients.

Register To Buy and Sell Shares

For more details on financing and valuation for Bolt Biotherapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Bolt Biotherapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Bolt Biotherapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Chih-Ping Liu Ph.D
Co-Founder & President
Randall Schatzman Ph.D
Chief Executive Officer & Board Member
Edgar Engleman
Co-Founder & Board Member
Grant Yonehiro
Chief Business Officer & Chief Operating Officer

Board Members

Ashish Khanna Ph.D
NFLS - Pivotal
Randall Schatzman Ph.D
Edgar Engleman
Peter Moldt
Richard Miller MD
Ken Harrison
Peter Bisgaard
Mahendra Shah

News Highlights

Bolt Biotherapeutics Expands Scientific Advisory Board with Appointment of Dr. Priti Hegde
/PRNewswire/ -- Bolt Biotherapeutics, Inc., a private biotechnology company focused on using its Immune-Stimulating Antibody Conjugate (ISAC) platform...
Bolt Bio preps clinical trials of immune-stimulating cancer drug in stubborn solid tumors
Bolt Biotherapeutics, founded by Stanford immuno-oncology veteran Edgar Engleman, is developing new class of cancer drugs called immune stimulating antibody conjugates. Backed by fresh data from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator, the company is preparing a phase 1 trial.
Xconomy: Bolt Bio Bags $54M for Drugs that Turn the Heat Up on “Cold” Tumors
In cancer lingo, “cold” tumors are cancers that the immune system doesn’t recognize or respond to, even when immune-stimulating drugs are given. Bolt
Updated on: Dec 1, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.